Generic Neurontin Availability

Neurontin is a brand name of gabapentin, approved by the FDA in the following formulation(s):

NEURONTIN (gabapentin - capsule;oral)

  • Manufacturer: PFIZER PHARMS
    Approval date: December 30, 1993
    Strength(s): 100MG [AB], 300MG [AB], 400MG [RLD] [AB]

NEURONTIN (gabapentin - solution;oral)

  • Manufacturer: PARKE DAVIS
    Approval date: March 2, 2000
    Strength(s): 250MG/5ML [RLD] [AA]

NEURONTIN (gabapentin - tablet;oral)

  • Manufacturer: PFIZER PHARMS
    Approval date: October 9, 1998
    Strength(s): 600MG [AB], 800MG [RLD] [AB]

Has a generic version of Neurontin been approved?

A generic version of Neurontin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Neurontin and have been approved by the FDA:

gabapentin capsule;oral

  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: September 12, 2003
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: ALKEM
    Approval date: December 17, 2010
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: AMNEAL PHARMS NY
    Approval date: July 25, 2007
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: APOTEX INC
    Approval date: April 6, 2005
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: AUROBINDO PHARM
    Approval date: January 31, 2008
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: HIKMA
    Approval date: September 25, 2007
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: INVAGEN PHARMS
    Approval date: December 30, 2009
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: MARKSANS PHARMA
    Approval date: July 21, 2011
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: MYLAN
    Approval date: February 14, 2011
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: RANBAXY
    Approval date: October 7, 2005
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: SUN PHARM INDS LTD
    Approval date: August 24, 2006
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: TARO
    Approval date: August 2, 2013
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: TEVA PHARMS
    Approval date: October 8, 2004
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]
  • Manufacturer: WATSON LABS
    Approval date: May 11, 2007
    Strength(s): 100MG [AB], 300MG [AB], 400MG [AB]

gabapentin solution;oral

  • Manufacturer: ACELLA PHARMS LLC
    Approval date: May 1, 2012
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: AMNEAL PHARMS
    Approval date: March 23, 2012
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: HI TECH PHARMA
    Approval date: February 18, 2011
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: TARO
    Approval date: July 3, 2013
    Strength(s): 250MG/5ML [AA]

gabapentin tablet;oral

  • Manufacturer: ACI HEALTHCARE LTD
    Approval date: July 12, 2013
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: ACTAVIS ELIZABETH
    Approval date: October 21, 2004
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: APOTEX INC
    Approval date: September 13, 2006
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: October 6, 2011
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: GLENMARK GENERICS
    Approval date: August 18, 2006
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: HIKMA PHARMS
    Approval date: July 21, 2011
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: INVAGEN PHARMS
    Approval date: October 16, 2012
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: IVAX SUB TEVA PHARMS
    Approval date: April 29, 2005
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: June 1, 2010
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: SUN PHARM INDS LTD
    Approval date: August 24, 2006
    Strength(s): 600MG [AB], 800MG [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: February 11, 2011
    Strength(s): 600MG [AB], 800MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Neurontin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Lactam-free amino acids
    Patent 6,054,482
    Issued: April 25, 2000
    Inventor(s): Augart; Helmut & Gebhardt; Uwe & Herrmann; Wolfgang
    Assignee(s): Godecke Aktiengesellschaft
    The present invention concerns cyclic amino acids of formula ##STR1## substantially free from the lactam ##STR2## wherein n is an integer of from 4 to 6, a process for the preparation thereof, compositions containing the compounds and methods of using them.
    Patent expiration dates:
    • April 25, 2017
    • October 25, 2017
      ✓ 
      Pediatric exclusivity
  • Liquid pharmaceutical compositions
    Patent 7,256,216
    Issued: August 14, 2007
    Inventor(s): Kulkarni; Neema M. & Schneider; Michael & Silbering; Steven B. & Meyer-Wonnay; Hans & Sanii-Yahyai; Nahid
    Assignee(s): Warner-Lambert Company LLC
    A liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0 and additionally a two-component liquid pharmaceutical composition comprising a first component comprising a powder mixture comprising a GABA analog and a solid polyhydric alcohol, and a second component comprising a liquid base are described, as well as methods to prepare the compositions and a method for treating cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine using a therapeutically effective amount of the pharmaceutical compositions.
    Patent expiration dates:
    • May 28, 2022
      ✓ 
      Drug product
    • November 28, 2022
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AAProducts in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web1)